Linda Collins

Linda F. Collins (April 17, 1962 – May 28, 2019; known as Linda Collins-Smith until her divorce) was an American businesswoman and politician who served a single term from 2015 to 2019 as a Republican member of the Arkansas Senate.

On June 4, 2019, she was found stabbed to death. Rebecca Lynn O'Donnell, a former campaign worker, was convicted of the murder. Provided by Wikipedia
Showing 1 - 3 results of 3 for search 'Linda Collins', query time: 0.01s Refine Results
  1. 1
    Europe needs a central, transparent, and evidence-based approval process for behavioural prevention interventions.

    Europe needs a central, transparent, and evidence-based approval process for behavioural prevention interventions. by Fabrizio Faggiano, Elias Allara, Fabrizia Giannotta, Roberta Molinar, Harry Sumnall, Reinout Wiers, Susan Michie, Linda Collins, Patricia Conrod

    Published 2014-10-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

    A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers by Peter Gallagher, Christian Rolfo, Elena Elez, Julien Taieb, Jennifer Houlden, Linda Collins, Corran Roberts, Thierry André, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Vlad Popovici, Alberto Bardelli, Robbie Carson, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Bryan T. Hennessy, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

    A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) by Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: